Other Events ·
At its reconvened 2026 Annual Meeting of Stockholders on July 8, 2026, Seres Therapeutics, Inc. stockholders approved…
MCRBSeres Therapeutics, Inc.
At its reconvened 2026 Annual Meeting of Stockholders on July 8, 2026, Seres Therapeutics, Inc. stockholders approved an amendment and restatement of the 2025 Incentive Award Plan to increase the number of shares available for issuance under the plan by 900,000 shares. The meeting was reconvened from its original June 9, 2026, meeting due to a lack of quorum. Three Class II directors were elected, and PricewaterhouseCoopers LLP was ratified as the company's independent auditor. Seres Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for gut microbiome-related diseases.